Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340

Showing 1-25 of 340 citing articles:

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hœlzemer, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 457-466.e4
Open Access | Times Cited: 1020
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1046-1057
Open Access | Times Cited: 532
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1161-1179
Open Access | Times Cited: 531
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Lok Bahadur Shrestha, Charles S. P. Foster, William D. Rawlinson, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 5
Open Access | Times Cited: 406
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Sandile Cele, Laurelle Jackson, David S. Khoury, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 342
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Frauke Muecksch, Zijun Wang, Alice Cho, et al.
Nature (2022) Vol. 607, Iss. 7917, pp. 128-134
Open Access | Times Cited: 268
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Jinyi Tang, Cong Zeng, Thomas M Cox, et al.
Science Immunology (2022) Vol. 7, Iss. 76
Open Access | Times Cited: 262
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 261
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau, Samuel M. S. Cheng, Kathy Leung, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 348-357
Open Access | Times Cited: 145
Viral persistence, reactivation, and mechanisms of long COVID
Benjamin K. Chen, Boris Jülg, Sindhu Mohandas, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 139
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 381-396
Open Access | Times Cited: 126
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion
Frederic Grabowski, Marek Kochańczyk, Tomasz Lipniacki
Viruses (2022) Vol. 14, Iss. 2, pp. 294-294
Open Access | Times Cited: 109
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hœlzemer, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 104
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
Sandile Cele, Laurelle Jackson, David S. Khoury, et al.
Nature (2021)
Open Access | Times Cited: 102
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
David S. Khoury, Timothy E. Schlub, Deborah Cromer, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 2, pp. 381-388
Open Access | Times Cited: 102
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
Yunlong Cao, Fanchong Jian, Zhiying Zhang, et al.
Cell Reports (2022) Vol. 41, Iss. 12, pp. 111845-111845
Open Access | Times Cited: 96
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
Yaniv Lustig, Tal Gonen, Lilac Meltzer, et al.
Nature Immunology (2022) Vol. 23, Iss. 6, pp. 940-946
Open Access | Times Cited: 92
Three-dose vaccination elicits neutralising antibodies against omicron
Mary Wu, Emma Wall, Edward J Carr, et al.
The Lancet (2022) Vol. 399, Iss. 10326, pp. 715-717
Open Access | Times Cited: 91
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Ranjan K. Mohapatra, Ruchi Tiwari, Ashish K. Sarangi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2336-2342
Open Access | Times Cited: 82
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 905-907
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top